Most importantly, we shed light on the potential molecular mechanisms by which RBMS1 promotes GC metastasis: it transactivates IL-6 and stimulates the JAK2/STAT3 downstream signaling pathway based on both in vitro and in vivo experiments, which suggests that RBMS1 may be a potential therapeutic target for GC. Here, JAK2 is linked to gastric cancer.